throbber
(cid:131) Monitor for symptoms or radiographic changes of interstitial lung
`disease (ILD). If ILD is suspected, discontinue TORISEL, and consider
`use of corticosteroids and/or antibiotics. (5.4)
`(cid:131)
`Bowel perforation may occur. Evaluate fever, abdominal pain, bloody
`stools, and/or acute abdomen promptly. (5.6)
`(cid:131)
`Renal failure, sometimes fatal, has occurred. Monitor renal function at
`baseline and while on TORISEL. (5.7)
`(cid:131) Due to abnormal wound healing, use TORISEL with caution in the
`perioperative period. (5.8)
`(cid:131)
`Live vaccinations and close contact with those who received live
`vaccines should be avoided. (5.12)
`(cid:131) Women of childbearing potential should be advised of the potential
`hazard to the fetus and to avoid becoming pregnant. (5.13)
`
`HIGHLIGHTS OF PRESCRIBING INFORMATION
`These highlights do not include all the information needed to use
`TORISEL™ safely and effectively. See full prescribing information for
`TORISEL.
`
`TORISEL™ Kit (temsirolimus) injection, for intravenous infusion only
`Initial U.S. approval: 2007
`
`--------------------INDICATIONS AND USAGE -----------------------
`TORISEL™ is a kinase inhibitor indicated for the treatment of advanced renal
`cell carcinoma. (1)
`
`--------------------DOSAGE AND ADMINISTRATION ---------- ----
`(cid:131)
`The recommended dose of TORISEL is 25 mg infused over a 30-60
`minute period once a week. Treat until disease progression or
`unacceptable toxicity. (2.1)
`(cid:131) Antihistamine pre-treatment is recommended. (2.2)
`(cid:131)
`TORISEL (temsirolimus) injection vial contents must first be diluted
`with the enclosed diluent before diluting the resultant solution with
`250 mL of 0.9% sodium chloride injection. (2.5)
`
`--------------------DOSAGE FORMS AND STRENGTHS -----------
`TORISEL injection, 25 mg/mL supplied with DILUENT for TORISEL. (3)
`
`-------------------------- CONTRAINDICATIONS ----------------------
`(cid:131) None. (4)
`
`
`---------------------------ADVERSE REACTIONS--------------------
`The most common adverse reactions (incidence ≥ 30%) are rash, asthenia,
`mucositis, nausea, edema, and anorexia. The most common laboratory
`abnormalities (incidence ≥30%) are anemia, hyperglycemia, hyperlipemia,
`hypertriglyceridemia, elevated alkaline phosphatase, elevated serum
`creatinine, lymphopenia, hypophosphatemia, thrombocytopenia, elevated
`AST, and leukopenia. (6)
`
`To report SUSPECTED ADVERSE REACTIONS, contact Wyeth
`Pharmaceuticals Inc. at 1-800-934-5556 or FDA at 1-800-FDA-1088 or
`www.fda.gov/medwatch.
`
`
`---------------------------DRUG INTERACTIONS----------------------
`--------------------WARNINGS AND PRECAUTIONS ---------------
`Strong inducers of CYP3A4/5 and inhibitors of CYP3A4 may affect
`(cid:131)
`To treat hypersensitivity reactions stop TORISEL and treat with an
`concentrations of the primary metabolite of TORISEL. If alternatives cannot
`antihistamine. TORISEL may be restarted at physician discretion at a
`be used, dose modifications of TORISEL are recommended. (7.1, 7.2)
`slower rate. (5.1)
`
`
`(cid:131) Hyperglycemia and hyperlipemia are likely and may require treatment.
`See 17 for PATIENT COUNSELING INFORMATION.
`Monitor glucose and lipid profiles. (5.2, 5.5)
`Revision date: 5/2007
`(cid:131)
`Infections may result from immunosuppression. (5.3)
`---------------------------------------------------------------------------------------------------------------------
`FULL PRESCRIBING INFORMATION: CONTENTS [*]
`7
`DRUG INTERACTIONS
`7.1
`Agents Inducing CYP3A Metabolism
`7.2
`Agents Inhibiting CYP3A Metabolism
`7.3
`Interactions with Drugs Metabolized by CYP2D6
`
`1
`
`2
`2.1
`2.2
`2.3
`2.4
`2.5
`
`INDICATIONS AND USAGE
`
`DOSAGE AND ADMINISTRATION
`Advanced Renal Cell Carcinoma
`Premedication
`Dosage Interruption/Adjustment
`Dose Modification Guidelines
`Instructions for Preparation and Administration
`
`3
`
`4
`
`5
`5.1
`5.2
`5.3
`5.4
`5.5
`5.6
`5.7
`5.8
`5.9
`5.10
`
`5.11
`5.12
`5.13
`5.14
`
`6
`6.1
`
`DOSAGE FORMS AND STRENGTHS
`
`CONTRAINDICATIONS
`
`WARNINGS AND PRECAUTIONS
`Hypersensitivity Reactions
`Hyperglycemia/Glucose Intolerance
`Infections
`Interstitial Lung Disease
`Hyperlipemia
`Bowel Perforation
`Renal Failure
`Wound Healing Complications
`Intracerebral Hemorrhage
`Co-administration with Inducers or Inhibitors of
`CYP3A Metabolism
`Concomitant use of TORISEL with sunitinib
`Vaccinations
`Pregnancy
`Monitoring Laboratory Tests
`
`ADVERSE REACTIONS
`Clinical Trials Experience
`
`*Sections or subsections omitted from the full prescribing information are not listed.
`1
`
`8
`8.1
`8.3
`8.4
`8.5
`8.6
`8.7
`
`10
`
`11
`
`12
`12.1
`12.3
`
`13
`13.1
`
`14
`
`15
`
`16
`
`17
`
`USE IN SPECIFIC POPULATIONS
`Pregnancy
`Nursing Mothers
`Pediatric Use
`Geriatric Use
`Renal Impairment
`Hepatic Impairment
`
`OVERDOSAGE
`
`DESCRIPTION
`
`CLINICAL PHARMACOLOGY
`Mechanism of Action
`Pharmacokinetics
`
`NONCLINICAL TOXICOLOGY
`Carcinogenesis, Mutagenesis, Impairment of
`Fertility
`
`CLINICAL STUDIES
`
`REFERENCES
`
`HOW SUPPLIED/STORAGE AND HANDLING
`
`PATIENT COUNSELING INFORMATION
`
`Ex. 1087-0001
`
`

`
`
`FULL PRESCRIBING INFORMATION
`1
`INDICATIONS AND USAGE
`TORISEL is indicated for the treatment of advanced renal cell carcinoma.
`2
`DOSAGE AND ADMINISTRATION
`2.1
`Advanced Renal Cell Carcinoma
`The recommended dose of TORISEL for advanced renal cell carcinoma is 25 mg infused over a
`30-60 minute period once a week.
`Treatment should continue until disease progression or unacceptable toxicity occurs.
`2.2
`Premedication
`Patients should receive prophylactic intravenous diphenhydramine 25 to 50 mg (or similar
`antihistamine) approximately 30 minutes before the start of each dose of TORISEL [see
`Hypersensitivity Reactions (5.1)].
`2.3
`Dosage Interruption/Adjustment
`TORISEL should be held for absolute neutrophil count (ANC) < 1,000/mm3, platelet count <
`75,000/mm3, or NCI CTCAE grade 3 or greater adverse reactions. Once toxicities have resolved
`to grade 2 or less, TORISEL may be restarted with the dose reduced by 5 mg/week to a dose no
`lower than 15 mg/week.
`2.4
`Dose Modification Guidelines
`Concomitant Strong CYP3A4 Inhibitors: The concomitant use of strong CYP3A4 inhibitors
`should be avoided (e.g. ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir,
`nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole). Grapefruit juice
`may also increase plasma concentrations of sirolimus (a major metabolite of temsirolimus) and
`should be avoided. If patients must be co-administered a strong CYP3A4 inhibitor, based on
`pharmacokinetic studies, a TORISEL dose reduction to 12.5 mg/week should be considered.
`This dose of TORISEL is predicted to adjust the AUC to the range observed without inhibitors.
`However, there are no clinical data with this dose adjustment in patients receiving strong
`CYP3A4 inhibitors. If the strong inhibitor is discontinued, a washout period of approximately 1
`week should be allowed before the TORISEL dose is adjusted back to the dose used prior to
`initiation of the strong CYP3A4 inhibitor. [see Drug Interactions (7.2)]
`
`Concomitant Strong CYP3A4 Inducers: The use of concomitant strong CYP3A4 inducers should
`be avoided (e.g. dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifampacin,
`phenobarbital). If patients must be co-administered a strong CYP3A4 inducer, based on
`pharmacokinetic studies, a TORISEL dose increase from 25 mg/week up to 50 mg/week should
`be considered. This dose of TORISEL is predicted to adjust the AUC to the range observed
`without inducers. However, there are no clinical data with this dose adjustment in patients
`receiving strong CYP3A4 inducers. If the strong inducer is discontinued the temsirolimus dose
`should be returned to the dose used prior to initiation of the strong CYP3A4 inducer. [see Drug
`Interactions (7.1)]
`
`2
`
`Ex. 1087-0002
`
`

`
`
`Instructions for Preparation and Administration
`2.5
`TORISEL must be stored under refrigeration at 2°-8°C (36°-46°F) and protected from light.
`During handling and preparation of admixtures, TORISEL should be protected from excessive
`room light and sunlight. Parenteral drug products should be inspected visually for particulate
`matter and discoloration prior to administration, whenever solution and container permit.
`In order to minimize the patient exposure to the plasticizer DEHP (di-2-ethylhexyl phthalate),
`which may be leached from PVC infusion bags or sets, the final TORISEL dilution for infusion
`should be stored in bottles (glass, polypropylene) or plastic bags (polypropylene, polyolefin) and
`administered through polyethylene-lined administration sets.
`
`Dilution:
`In preparing the TORISEL administration solution, follow this two-step dilution process in an
`aseptic manner.
`Step 1:
`Inject 1.8 mL of DILUENT for TORISEL into the vial of TORISEL (temsirolimus) injection (25
`mg/ml). The TORISEL (temsirolimus) vial contains an overfill of 0.2 mL (30 mg/1.2 mL). Due
`to the intentional overfill in the TORISEL injection vial, the drug concentration of the resulting
`solution will be 10 mg/mL. A total volume of 3 mL will be obtained including the overfill. Mix
`well by inversion of the vial. Allow sufficient time for air bubbles to subside. This 10 mg/mL
`drug solution/diluent mixture must be further diluted as described in Step 2 below.
`The solution is clear to slightly turbid, colorless to yellow, and free from visual particulates. The
`10 mg/mL drug solution/diluent mixture is stable for up to 24 hours at controlled room
`temperature.
`Step 2:
`Withdraw the required amount of temsirolimus from the 10 mg/mL drug solution/diluent mixture
`prepared in Step 1. Inject rapidly into a 250 mL container (glass, polyolefin, or polyethylene) of
`0.9% sodium chloride injection. Mix the admixture by inversion of the bag or bottle. Avoid
`excessive shaking as this may cause foaming.
`Administration:
`The sodium chloride injection container should be composed of non-DEHP containing
`materials, such as glass, polyolefin or polyethylene, and the administration set should
`consist of non-DEHP tubing to avoid extraction of di-(2-ethylhexyl) phthalate (DEHP).
`TORISEL contains polysorbate 80, which is known to increase the rate of di-(2-
`ethylhexyl) phthalate (DEHP) extraction from PVC.
`An in-line polyethersulfone filter with a pore size of not greater than 5 microns is
`recommended for administration.
`The final diluted solution of TORISEL is intravenously infused over a 30-60 minute
`period once a week. The use of an infusion pump is the preferred method of
`administration to ensure accurate delivery of the drug.
`
`•
`
`•
`
`•
`
`3
`
`Ex. 1087-0003
`
`

`
`
`•
`
`Administration of the final diluted infusion solution should be completed within six hours
`from the time that the drug solution/diluent mixture is added to the sodium chloride
`injection.
`Compatibilities and Incompatibilities
`Undiluted TORISEL injection should not be added directly to aqueous infusion solutions. Direct
`addition of TORISEL injection to aqueous solutions will result in precipitation of drug. Always
`combine TORISEL injection with DILUENT for TORISEL before adding to infusion solutions.
`It is recommended that TORISEL be administered in 0.9% sodium chloride injection after
`combining with diluent. The stability of TORISEL in other infusion solutions has not been
`evaluated. Addition of other drugs or nutritional agents to admixtures of TORISEL in sodium
`chloride injection has not been evaluated and should be avoided. Temsirolimus is degraded by
`both acids and bases, and thus combinations of temsirolimus with agents capable of modifying
`solution pH should be avoided.
`3
`DOSAGE FORMS AND STRENGTHS
`TORISEL (temsirolimus) is supplied as a kit consisting of the following:
`•
`TORISEL (temsirolimus) injection (25 mg/ml). The TORISEL vial includes an overfill of
`0.2 mL.
`DILUENT for TORISEL. The DILUENT vial includes a deliverable volume of 1.8 mL.
`
`•
`
`CONTRAINDICATIONS
`
`4
`None.
`WARNINGS AND PRECAUTIONS
`5
`5.1 Hypersensitivity Reactions
`Hypersensitivity reactions manifested by symptoms including, but not limited to, anaphylaxis,
`dyspnea, flushing, and chest pain have been observed with TORISEL.
`TORISEL should be used with caution in persons with known hypersensitivity to temsirolimus
`or its metabolites (including sirolimus), polysorbate 80, or to any other component (including the
`excipients) of TORISEL.
`An H1 antihistamine should be administered to patients before the start of the intravenous
`temsirolimus infusion. TORISEL should be used with caution in patients with known
`hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other
`medical reasons.
`If a patient develops a hypersensitivity reaction during the TORISEL infusion, the infusion
`should be stopped and the patient should be observed for at least 30 to 60 minutes (depending on
`the severity of the reaction). At the discretion of the physician, treatment may be resumed with
`the administration of an H1-receptor antagonist (such as diphenhydramine), if not previously
`administered [see Dosage and Administration (2.2)], and/or an H2-receptor antagonist (such as
`intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before
`
`4
`
`Ex. 1087-0004
`
`

`
`
`restarting the TORISEL infusion. The infusion may then be resumed at a slower rate (up to 60
`minutes).
`5.2 Hyperglycemia/Glucose Intolerance
`The use of TORISEL is likely to result in increases in serum glucose. In the phase 3 trial, 89% of
`patients receiving TORISEL had at least one elevated serum glucose while on treatment, and
`26% of patients reported hyperglycemia as an adverse event. This may result in the need for an
`increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. Serum
`glucose should be tested before and during treatment with TORISEL. Patients should be advised
`to report excessive thirst or any increase in the volume or frequency of urination.
`5.3
`Infections
`The use of TORISEL may result in immunosuppression. Patients should be carefully observed
`for the occurrence of infections, including opportunistic infections [see Adverse Reactions (6.1)].
`
`Interstitial Lung Disease
`5.4
`Cases of interstitial lung disease, some resulting in death, occurred in patients who received
`TORISEL. Some patients were asymptomatic with infiltrates detected on computed tomography
`scan or chest radiograph. Others presented with symptoms such as dyspnea, cough, hypoxia, and
`fever. Some patients required discontinuation of TORISEL and/or treatment with corticosteroids
`and/or antibiotics, while some patients continued treatment without additional intervention.
`Patients should be advised to report promptly any new or worsening respiratory symptoms.
`
`5.5 Hyperlipemia
`The use of TORISEL is likely to result in increases in serum triglycerides and cholesterol. In the
`phase 3 trial, 87% of patients receiving TORISEL had at least one elevated serum cholesterol
`value and 83% had at least one elevated serum triglyceride value. This may require initiation, or
`increase in the dose, of lipid-lowering agents. Serum cholesterol and triglycerides should be
`tested before and during treatment with TORISEL.
`
`Bowel Perforation
`5.6
`Cases of fatal bowel perforation occurred in patients who received TORISEL. These patients
`presented with fever, abdominal pain, metabolic acidosis, bloody stools, diarrhea, and/or acute
`abdomen. Patients should be advised to report promptly any new or worsening abdominal pain
`or blood in their stools.
`5.7
`Renal Failure
`Cases of rapidly progressive and sometimes fatal acute renal failure not clearly related to disease
`progression occurred in patients who received TORISEL. Some of these cases were not
`responsive to dialysis.
`5.8 Wound Healing Complications
`Use of TORISEL has been associated with abnormal wound healing. Therefore, caution should
`be exercised with the use of TORISEL in the perioperative period.
`
`
`5
`
`Ex. 1087-0005
`
`

`
`Intracerebral Hemorrhage
`
`
`5.9
`
`Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving
`anticoagulation therapy may be at an increased risk of developing intracerebral bleeding
`(including fatal outcomes) while receiving TORISEL.
`5.10 Co-administration with Inducers or Inhibitors of CYP3A Metabolism
`Agents Inducing CYP3A Metabolism:
`
`Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital,
`rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. If
`alternative treatment cannot be administered, a dose adjustment should be considered. St. John’s
`Wort may decrease TORISEL plasma concentrations unpredictably. Patients receiving
`TORISEL should not take St. John’s Wort concomitantly. [see Dosage and Administration (2.4)
`and Drug Interactions (7.1)].
`
`Agents Inhibiting CYP3A Metabolism:
`Strong CYP3A4 inhibitors such as atazanavir, clarithromycin, indinavir, itraconazole,
`ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin may increase blood
`concentrations of the active metabolite sirolimus. If alternative treatments cannot be
`administered, a dose adjustment should be considered. [see Dosage and Administration (2.4) and
`Drug Interactions (7.2)].
`
`5.11 Concomitant use of TORISEL with sunitinib
`
`The combination of TORISEL and sunitinib resulted in dose-limiting toxicity. Dose-limiting
`toxicities (Grade 3/4 erythematous maculopapular rash, and gout/cellulitis requiring
`hospitalization) were observed in two out of three patients treated in the first cohort of a phase 1
`study at doses of TORISEL 15 mg IV per week and sunitinib 25 mg oral per day (Days 1-28
`followed by a 2-week rest).
`5.12 Vaccinations
`The use of live vaccines and close contact with those who have received live vaccines should be
`avoided during treatment with TORISEL. Examples of live vaccines are: intranasal influenza,
`measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines.
`
`5.13 Pregnancy
`Pregnancy Category D
`Temsirolimus administered daily as an oral formulation caused embryo-fetal and intrauterine
`toxicities in rats and rabbits at human sub-therapeutic exposures. Embryo-fetal adverse effects in
`rats consisted of reduced fetal weight and reduced ossifications, and in rabbits included reduced
`fetal weight, omphalocele, bifurcated sternabrae, notched ribs, and incomplete ossifications.
`In rats, the intrauterine and embryo-fetal adverse effects were observed at the oral dose of 2.7
`mg/m2/day (approximately 0.04-fold the AUC in cancer patients at the human recommended
`dose). In rabbits, the intrauterine and embryo-fetal adverse effects were observed at the oral
`
`6
`
`Ex. 1087-0006
`
`

`
`
`dose of ≥7.2 mg/m2/day (approximately 0.12-fold the AUC in cancer patients at the
`recommended human dose).
`Women of childbearing potential should be advised to avoid becoming pregnant throughout
`treatment and for 3 months after TORISEL therapy has stopped. Temsirolimus can cause fetal
`harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the
`patient becomes pregnant while taking this drug, the patient should be apprised of the potential
`hazard to the fetus.
`Men should be counseled regarding the effects of TORISEL on the fetus and sperm prior to
`starting treatment [see Nonclinical Toxicology (13.1)]. Men with partners of childbearing
`potential should use reliable contraception throughout treatment and are recommended to
`continue this for 3 months after the last dose of TORISEL.
`5.14 Monitoring Laboratory Tests
`In the randomized, phase 3 trial, complete blood counts (CBCs) were checked weekly, and
`chemistry panels were checked every two weeks. Laboratory monitoring for patients receiving
`TORISEL may need to be performed more or less frequently at the physician’s discretion.
`6
`ADVERSE REACTIONS
`The following serious adverse reactions have been associated with TORISEL in clinical trials
`and are discussed in greater detail in other sections of the label [see Warnings and Precautions
`(5)].
`Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
`Hyperglycemia/Glucose Intolerance [see Warnings and Precautions (5.2)]
`Interstitial Lung Disease [see Warnings and Precautions (5.4)]
`Hyperlipemia [see Warnings and Precautions (5.5)]
`Bowel Perforation [see Warnings and Precautions (5.6)]
`Renal Failure (see Warnings and Precautions (5.7)]
`The most common (≥ 30%) adverse reactions observed with TORISEL are rash, asthenia,
`mucositis, nausea, edema, and anorexia. The most common (≥ 30%) laboratory abnormalities
`observed with TORISEL are anemia, hyperglycemia, hyperlipemia, hypertriglyceridemia,
`lymphopenia, elevated alkaline phosphatase, elevated serum creatinine, hypophosphatemia,
`thrombocytopenia, elevated AST, and leukopenia.
`6.1
`Clinical Trials Experience
`Because clinical trials are conducted under widely varying conditions, the adverse reaction rates
`observed cannot be directly compared to rates in other trials and may not reflect the rates
`observed in clinical practice.
`In the Phase 3 randomized, open-label study of interferon alfa (IFN-α) alone, TORISEL alone,
`and TORISEL and IFN-α, a total of 616 patients were treated. Two hundred patients received
`IFN-α weekly, 208 received TORISEL 25 mg weekly, and 208 patients received a combination
`of TORISEL and IFN-α weekly [see Clinical Studies (14)].
`
`7
`
`Ex. 1087-0007
`
`

`
`
`Treatment with the combination of TORISEL 15 mg and IFN-α was associated with an increased
`incidence of multiple adverse reactions and did not result in a significant increase in overall
`survival when compared with IFN-α alone.
`Table 1 shows the percentage of patients experiencing treatment emergent adverse reactions.
`Reactions reported in at least 10% of patients who received TORISEL 25 mg alone or IFN-α
`alone are listed. Table 2 shows the percentage of patients experiencing selected laboratory
`abnormalities. Data for the same adverse reactions and laboratory abnormalities in the IFN-α
`alone arm are shown for comparison.
`Table 1 –Adverse Reactions Reported in at Least 10% of Patients Who Received
`25 mg IV TORISEL or IFN-α in the Randomized Trial
`TORISEL
`25 mg
`n=208
`
`IFN-α
`
`n=200
`
`Grades
`3&4*
`n (%)
`
`155 (78)
`
`52 (26)
`1 (1)
`4 (2)
`7 (4)
`4 (2)
`0 (0)
`2 (1)
`3 (2)
`
`0 (0)
`8 (4)
`9 (5)
`4 (2)
`3 (2)
`1 (1)
`5 (3)
`
`4 (2)
`3 (2)
`0 (0)
`0 (0)
`
`
`
`7 (4)
`2 (1)
`
`All
`Grades*
`n (%)
`
`199 (100)
`
`127 (64)
`21 (11)
`31 (16)
`99 (50)
`50 (25)
`30 (15)
`18 (9)
`59 (30)
`
`19 (10)
`87 (44)
`82 (41)
`40 (20)
`34 (17)
`36 (18)
`57 (29)
`
`19 (10)
`24 (12)
`3 (2)
`4 (2)
`
`
`
`28 (14)
`29 (15)
`
`Grades
`3&4*
`n (%)
`
`139 (67)
`
`23 (11)
`7 (3)
`10 (5)
`1 (1)
`3 (1)
`1 (1)
`2 (1)
`1(1)
`
`6 (3)
`6 (3)
`5 (2)
`3 (1)
`9 (4)
`0 (0)
`4 (2)
`
`6 (3)
`3 (1)
`0 (0)
`0 (0)
`
`
`
`6 (3)
`2 (1)
`
`All
`Grades*
`n (%)
`
`208 (100)
`
`106 (51)
`73 (35)
`59 (28)
`50 (24)
`39 (19)
`31 (15)
`34 (16)
`17 (8)
`
`86 (41)
`66 (32)
`77 (37)
`56 (27)
`44 (21)
`42 (20)
`40 (19)
`
`42 (20)
`31 (15)
`25 (12)
`20 (10)
`
`
`
`41 (20)
`37 (18)
`
`8
`
`Adverse Reaction
`
`
`Any
`General disorders
`Asthenia
`Edemaa
`Pain
`Pyrexia
`Weight Loss
`Headache
`Chest Pain
`Chills
`Gastrointestinal disorders
`Mucositisb
`Anorexia
`Nausea
`Diarrhea
`Abdominal Pain
`Constipation
`Vomiting
`Infections
`Infectionsc
`Urinary tract infectiond
`Pharyngitis
`Rhinitis
`Musculoskeletal and
`connective tissue disorders
`Back Pain
`Arthralgia
`
`Ex. 1087-0008
`
`

`
`
`
`Adverse Reaction
`
`
`Any
`
`Myalgia
`Respiratory, thoracic and
`mediastinal disorders
`Dyspnea
`Cough
`Epistaxis
`Skin and subcutaneous tissue
`disorders
`Rashe
`Pruritus
`Nail Disorder
`Dry Skin
`Acne
`Nervous system disorders
`Dysgeusiaf
`Insomnia
`Depression
`
` *
`
` Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0.
`a Includes edema, facial edema, and peripheral edema
`b Includes aphthous stomatitis, glossitis, mouth ulceration, mucositis, and stomatitis
`c Includes infections not otherwise specified (NOS) and the following infections that occurred infrequently as
`distinct entities: abscess, bronchitis, cellulitis, herpes simplex, and herpes zoster
`d Includes cystitis, dysuria, hematuria, urinary frequency, and urinary tract infection
`e Includes eczema, exfoliative dermatitis, maculopapular rash, pruritic rash, pustular rash, rash (NOS), and
`vesiculobullous rash
`f Includes taste loss and taste perversion
`
`The following selected adverse reactions were reported less frequently (<10%).
`Gastrointestinal Disorders – Fatal bowel perforation occurred in 1 patient (1%).
`Eye Disorders - Conjunctivitis (including lacrimation disorder) occurred in 15 patients (7%).
`Immune System - Allergic/Hypersensitivity reactions occurred in 18 patients (9%).
`Angioneurotic edema-type reactions have been observed in some patients who received
`TORISEL and ACE inhibitors concomitantly.
`
`9
`
`Table 1 –Adverse Reactions Reported in at Least 10% of Patients Who Received
`25 mg IV TORISEL or IFN-α in the Randomized Trial
`TORISEL
`25 mg
`n=208
`
`IFN-α
`
`n=200
`
`Grades
`3&4*
`n (%)
`
`155 (78)
`2 (1)
`
`
`
`11 (6)
`0 (0)
`0 (0)
`
`
`
`0(0)
`0 (0)
`0 (0)
`0 (0)
`0 (0)
`
`0 (0)
`0 (0)
`4 (2)
`
`All
`Grades*
`n (%)
`
`199 (100)
`29 (15)
`
`
`
`48 (24)
`29 (15)
`7 (4)
`
`
`
`14 (7)
`16 (8)
`1 (1)
`14 (7)
`2 (1)
`
`17 (9)
`30 (15)
`27 (14)
`
`Grades
`3&4*
`n (%)
`
`139 (67)
`1 (1)
`
`
`
`18 (9)
`2 (1)
`0 (0)
`
`
`
`10 (5)
`1 (1)
`0 (0)
`1 (1)
`0 (0)
`
`0 (0)
`1 (1)
`0 (0)
`
`All
`Grades*
`n (%)
`
`208 (100)
`16 (8)
`
`
`
`58 (28)
`53 (26)
`25 (12)
`
`
`
`97 (47)
`40 (19)
`28 (14)
`22 (11)
`21 (10)
`
`41 (20)
`24 (12)
`9 (4)
`
`Ex. 1087-0009
`
`

`
`
`Infections - Pneumonia occurred in 17 patients (8%); upper respiratory tract infection occurred in
`14 patients (7%).
`General Disorders and Administration Site Conditions - Impaired wound healing occurred in
`3 patients (1%).
`Respiratory, Thoracic and Mediastinal Disorders – Interstitial lung disease occurred in 5 patients
`(2%), including rare fatalities.
`Vascular - Hypertension occurred in 14 patients (7%); venous thromboembolism (including deep
`vein thrombosis and pulmonary embolus) occurred in 5 patients (2%); thrombophlebitis occurred
`in 2 patients (1%).
`Table 2 – Incidence of Selected Laboratory Abnormalities in Patients Who Received
`25 mg IV TORISEL or IFN-α in the Randomized Trial
`TORISEL
`25 mg
`n=208
`Grades
`3&4*
`n (%)
`
`IFN-α
`
`n=200
`Grades
`3&4*
`n (%)
`
`All
`Grades*
`n (%)
`
`
`195 (98)
`
`180 (90)
`106 (53)
`58 (29)
`51 (26)
`93 (47)
`
` 111 (56)
`103 (52)
` 97 (49)
` 128 (64)
`61 (31)
` 25 (13)
`95 (48)
`144 (72)
`15 (8)
`
`Laboratory Abnormality
`
`All
`Grades*
`n (%)
`
`
`Any
`Hematology
`Hemoglobin Decreased
`Lymphocytes Decreased**
`Neutrophils Decreased**
`Platelets Decreased
`Leukocytes Decreased
`Chemistry
`Alkaline Phosphatase Increased
`AST Increased
`Creatinine Increased
`Glucose Increased
`Phosphorus Decreased
`Total Bilirubin Increased
`Total Cholesterol Increased
`Triglycerides Increased
`Potassium Decreased
`*NCI CTC version 3.0
`**Grade 1 toxicity may be under-reported for lymphocytes and neutrophils
`
`208 (100)
`
`162 (78)
`
`195 (94)
`110 (53)
`39 (19)
`84 (40)
`67 (32)
`
` 141 (68)
` 79 (38)
` 119 (57)
` 186 (89)
`102 (49)
` 16 (8)
`181 (87)
`173 (83)
`43 (21)
`
`41 (20)
`33 (16)
`10 (5)
`3 (1)
`1 (1)
`
` 7 (3)
` 5 (2)
` 7 (3)
` 33 (16)
` 38 (18)
` 2 (1)
`5 (2)
`92 (44)
`11 (5)
`
`144 (72)
`
`43 (22)
`48 (24)
`19 (10)
`0 (0)
`11 (6)
`
`13 (7)
` 14 (7)
` 2 (1)
` 6 (3)
` 17 (9)
` 4 (2)
`2 (1)
`69 (35)
`0 (0)
`
` 7
`
`DRUG INTERACTIONS
`
`Agents Inducing CYP3A Metabolism
`7.1
`Co-administration of TORISEL with rifampin, a potent CYP3A4/5 inducer, had no significant
`effect on temsirolimus Cmax (maximum concentration) and AUC (area under the concentration
`
`10
`
`Ex. 1087-0010
`
`

`
`
`versus the time curve) after intravenous administration, but decreased sirolimus Cmax by 65% and
`AUC by 56% compared to TORISEL treatment alone. If alternative treatment cannot be
`administered, a dose adjustment should be considered [see Dosage and Administration (2.4)].
`7.2
`Agents Inhibiting CYP3A Metabolism
`Co-administration of TORISEL with ketoconazole, a potent CYP3A4 inhibitor, had no
`significant effect on temsirolimus Cmax or AUC; however, sirolimus AUC increased 3.1-fold, and
`Cmax increased 2.2-fold compared to TORISEL alone. If alternative treatment cannot be
`administered, a dose adjustment should be considered. [see Dosage and Administration (2.4)].
`7.3
`Interactions with Drugs Metabolized by CYP2D6
`The concentration of desipramine, a CYP2D6 substrate, was unaffected when 25 mg of
`TORISEL was co-administered. No clinically significant effect is anticipated when temsirolimus
`is co-administered with agents that are metabolized by CYP2D6 or CYP3A4.
`8
`USE IN SPECIFIC POPULATIONS
`8.1
`Pregnancy
`Pregnancy Category D [see Warnings and Precautions (5.13)].
`8.3
`Nursing Mothers
`It is not known whether TORISEL is excreted into human milk, and due to the potential for
`tumorigenicity shown for sirolimus (active metabolite of TORISEL) in animal studies, a decision
`should be made whether to discontinue nursing or discontinue TORISEL, taking into account the
`importance of the drug to the mother.
`8.4
`Pediatric Use
`The safety and effectiveness of TORISEL in pediatric patients have not been established.
`8.5 Geriatric Use
`Clinical studies of TORISEL did not include sufficient numbers of subjects aged 65 and older to
`determine whether they respond differently from younger subjects.
`
`Renal Impairment
`8.6
`No clinical studies were conducted with TORISEL in patients with decreased renal function.
`Less than 5% of total radioactivity was excreted in the urine following a 25 mg intravenous dose
`of [14C]-labeled temsirolimus in healthy subjects. Renal impairment is not expected to markedly
`influence drug exposure, and no dosage adjustment of TORISEL is recommended in patients
`with renal impairment.
`TORISEL has not been studied in patients undergoing hemodialysis.
`8.7 Hepatic Impairment
`Temsirolimus is cleared predominantly by the liver. No data are currently available regarding
`the influence of hepatic dysfunction on temsirolimus disposition.
`
`11
`
`Ex. 1087-0011
`
`

`
`
`10
`OVERDOSAGE
`There is no specific treatment for TORISEL intravenous overdose. TORISEL
`has been administered to patients with cancer in phase 1 and 2 trials with repeated intravenous
`doses as high as 220 mg/m2. The risk of several serious adverse events, including thrombosis,
`bowel perforation, interstitial lung disease (ILD), seizure, and psychosis, is increased with doses
`of TORISEL greater than 25 mg.
`11
`DESCRIPTION
`Temsirolimus, an inhibitor of mTOR, is an antineoplastic agent.
`Temsirolimus is a white to off-white powder with a molecular formula of C56H87NO16 and a
`molecular weight of 1030.30. It is non-hygroscopic. Temsirolimus is practically insoluble in
`water and soluble in alcohol. It has no ionizable functional groups, and its solubility is
`independent of pH.
`The chemical name of temsirolimus is
`(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,
`26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-
`methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexameth3H-pyrido[2,1-
`c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone 4′-[2,2-
`bis(hydroxymethyl)propionate]; or Rapamycin, 42-[3-hydroxy-2-(hydroxymethyl)-
`2-methylpropanoate].
`
`OH
`OH
`
`H3C
`
`O
`
`O
`OCH3
`
`O
`
`N
`
`CH3
`OH
`
`O
`
`O
`
`O
`CH3
`
`H3CO
`
`O
`
`CH3
`
`O
`
`H3C
`
`H3C
`O
`
`CH3
`
`OH
`
`OCH3
`
`CH3
`
`
`TORISEL (temsirolimus) injection, 25 mg/mL, is a clear, colorless to light-yellow, non-aqueous,
`ethanolic, sterile solution. TORISEL (temsirolimus) injection requires two dilutions prior to
`intravenous infusion. TORISEL (temsirolimus) injection should be diluted only with the supplied
`DILUENT for TORISEL.
`DILUENT for TORISEL is a sterile, non-aqueous solution that is supplied with TORISEL
`injection, as a kit.
`TORISEL (temsirolimus) injection, 25 mg/mL:
`Active ingredient: temsirolimus (25 mg/mL)
`
`12
`
`Ex. 1087-0012
`
`

`
`
`Inactive ingredients: dehydrated alcohol (39.5% w/v), dl-alpha-tocopherol (0.075% w/v),
`propylene glycol (50.3% w/v), and anhydrous citric acid (0.0025% w/v).
`DILUENT for TORISEL
`Inactive ingredients: polysorbate 80 (40.0% w/v), polyethylene glycol 400 (42.8% w/v), and
`dehydrated alcohol (19.9%w/v).
`After the TORISEL (temsirolimus) injection vial

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket